Liver International最新文献

{"title":"Differential Pathways Orchestrate Plasma-Cell Infiltration in Liver Autoimmunity Diseases","authors":"L. Baert,&nbsp;Z. Chemkhi,&nbsp;B. Manfroi,&nbsp;M. Mesples,&nbsp;L. David-Boudet,&nbsp;E. Col,&nbsp;K. Harada,&nbsp;B. Huard,&nbsp;N. Sturm","doi":"10.1111/liv.70093","DOIUrl":"https://doi.org/10.1111/liv.70093","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background &amp; Aims</h3>\u0000 \u0000 <p>Plasma cells (PCs) are frequently infiltrating livers from autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). However, the molecular pathway(s) implicated remain largely undefined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective in situ study was performed to assess the cells and molecules involved in PC chemotactism and survival. Relevant in vitro assays were conducted to confirm the activity of the identified molecules.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We found that myeloid cells producing the PC survival factor a proliferation-inducing ligand (APRIL) were present in livers from both diseases. Notably, APRIL density both at the level of producing cells and tissue retention of their secreted product correlated with PC accumulation in portal tracts from AIH but not PBC. PCs from AIH livers expressed the B-cell maturation antigen and CD138 as the APRIL (co)receptors. Consequently, AIH liver PCs responded to APRIL stimulation with an increase in vitro survival. We further identified IL-16 produced by infiltrating lymphocytes as a chemokine involved in PC recruitment. IL-16 expression also correlated with PC accumulation in portal spaces from AIH but again not from PBC. Follow-up biopsies in AIH showed that treatment expectedly reduced PC density and affected in a similar way the density of APRIL-producing cells. Notably, the density of secreted APRIL was less affected. Finally, the density of IL-16-producing cells was not affected.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our data show that PC infiltration and persistence is under the guidance of different pathways in AIH and PBC. In AIH, treatment leaves the PC chemotactism pathway unaffected, while partly downregulating the survival pathway.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 5","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the Letter to the Editor: Real-World Case Supporting Drug-Induced Autoimmune Hepatitis","authors":"Yu Wang,&nbsp;Xinyan Zhao","doi":"10.1111/liv.70087","DOIUrl":"https://doi.org/10.1111/liv.70087","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 5","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143822010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MASLD And MASH Risk: Does Losing Obesity Reverse the Metabolic Footprint?","authors":"Mohamed El-Kassas,&nbsp;Khalid Alswat,&nbsp;Khalid M. AlNaamani","doi":"10.1111/liv.70095","DOIUrl":"https://doi.org/10.1111/liv.70095","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 5","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143822009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Bacterial Infections in Patients With Cirrhosis Between Hospitals With and Without Liver Transplant in Catalonia","authors":"Clàudia Torras,&nbsp;Juan Bañares,&nbsp;Aina Martí-Carretero,&nbsp;Víctor Acin,&nbsp;Laura Pagès,&nbsp;Laura Gutiérrez-Rios,&nbsp;Antonio Casabella,&nbsp;José Ferrusquía-Acosta,&nbsp;Jordi Sánchez-Delgado,&nbsp;Martina Pérez,&nbsp;Diana Fuertes,&nbsp;Marta Garcia-Guix,&nbsp;Berta Cuyàs,&nbsp;Helena Masnou,&nbsp;Alberto Amador,&nbsp;German Soriano,&nbsp;Juan M. Pericàs,&nbsp;Oriol Gasch,&nbsp;Cristina Solé","doi":"10.1111/liv.70076","DOIUrl":"https://doi.org/10.1111/liv.70076","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Infections by multidrug resistant (MDR) bacteria are increasing and vary across regions and hospitals. We aimed to assess the epidemiology, prevalence, and outcomes of bacterial infections in patients with decompensated cirrhosis, comparing liver transplant (LT) and non-LT centers in Catalonia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This is a multicenter retrospective study including all patients with decompensated cirrhosis and bacterial infections hospitalised between January 2021 and 2022 from 5 university hospitals in the Barcelona metropolitan area. Two of them were LT centres. Clinical, laboratory, microbiological data, and in-hospital mortality were collected.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 576 infections were reported in 352 patients. LT centers had more health-related infections, recurrent infections, and septic shock than non-LT centers, while there were no differences in cirrhosis severity, acute-on-chronic liver failure (ACLF) or comorbidities. Although the most commonly isolated microorganisms and types of infection were similar in both centers, LT centers had higher rates of extended-spectrum beta-lactamase (12% vs. 6%), carbapenem (3% vs. 0%) and piperacillin-tazobactam resistant bacteria (14% vs. 7%). MDR rate was also higher in LT centers (38% vs. 25%, <i>p</i> = 0.02) and varied across hospitals (18%–42%, <i>p</i> &lt; 0.05). Furthermore, in-hospital mortality was higher in LT centers (20% vs. 10%; <i>p</i> = 0.01). Independent predictors of in-hospital mortality were septic shock, ACLF, Child-Pugh, age, and leukocyte count.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our study showed differences in epidemiology, prevalence of MDR infections, and outcomes across university hospitals, particularly between centers with and without LT. Further studies are warranted to unveil the nuances of bacterial infections across different healthcare institutions in Europe and elsewhere.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 5","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143818705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neddylation and MASLD: From Pathophysiology to Therapy","authors":"Wenjun Lin,&nbsp;Wenfang Zheng,&nbsp;Nuo Dai,&nbsp;Yulian Wu,&nbsp;Xiaofeng Zhang","doi":"10.1111/liv.70064","DOIUrl":"https://doi.org/10.1111/liv.70064","url":null,"abstract":"<p>Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is intimately linked to the dysregulation of key transcription factors or enzymes involved in hepatic metabolism. Neddylation, a post-translational modification, refers to the covalent attachment of neuronal precursor cell-expressed developmentally down-regulated 8 (Nedd8) to specific substrates and plays a significant role in regulating protein conformation, localisation and activity. The connection between neddylation and MASLD is a burgeoning area of research that is presently the focus of extensive study. In this review, we focus on the latest advancements regarding the role of neddylation in various critical pathological stages of MASLD. We summarise both the confirmed and potential evidence of neddylation's involvement in the onset and progression of MASLD. Additionally, we review the biological basis of neddylation, its correlation with the progression of MASLD and propose potential directions for basic and translational research in this field. Finally, we emphasise the potential therapeutic applications of targeting neddylation in MASLD, particularly in designing pharmacological inhibitors that have broad effects on MASLD.</p>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 5","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70064","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis","authors":"Federico Piñero,&nbsp;Margarita Anders,&nbsp;Carla Bermudez,&nbsp;Diego Arufe,&nbsp;Adriana Varón,&nbsp;Ana Palazzo,&nbsp;Jorge Rodriguez,&nbsp;Oscar Beltrán,&nbsp;Daniela Simian,&nbsp;Leonardo Gomes da Fonseca,&nbsp;Ezequiel Ridruejo,&nbsp;Norberto Tamagnone,&nbsp;Hugo Cheinquer,&nbsp;Diana Bejarano,&nbsp;Juan Ignacio Marín,&nbsp;Federico Orozco,&nbsp;Josefina Pages,&nbsp;Jaime Poniachik,&nbsp;Sebastián Marciano,&nbsp;Virginia Reggiardo,&nbsp;Marcelo Silva,&nbsp;Manuel Mendizabal","doi":"10.1111/liv.70092","DOIUrl":"https://doi.org/10.1111/liv.70092","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>The survival outcomes associated with hepatic recompensation in patients with advanced hepatocellular carcinoma (HCC) treated with first-line systemic therapies remain unclear. We compared survival from the initiation of first-line systemic treatments for advanced HCC among patients with compensated, decompensated, and recompensated cirrhosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A Latin American multicenter, prospective cohort study was conducted from 2018 to 2024, involving patients with HCC and Child-Pugh class A or B who received systemic therapy. At the time of first-line therapy, patients with cirrhosis were categorised as compensated (never decompensated), decompensated, or recompensated. Cox proportional hazards models were estimated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 306 patients receiving first-line systemic therapy (sorafenib: 60.5%, atezolizumab + bevacizumab: 29.7%, lenvatinib: 9.1%), 240 had cirrhosis, with 30.4% having a history of hepatic decompensation. Of these, 57.5% (95% CI 45.4%–69.0%) achieved hepatic recompensation over a median period of 12 months. At the time of first-line therapy, 69.6% were compensated, 17.5% recompensated, and 12.9% decompensated. Metabolic-associated steatotic liver disease (MASLD) was the most common underlying aetiology in the recompensated group. Median survival was significantly shorter in the decompensated group (8.6 months) compared to the compensated group (17.2 months) [aHR 1.91 (95% CI 1.04–3.5); <i>p</i> = 0.03], without a significant difference between the recompensated and compensated groups [aHR 1.28 (95% CI 0.79–2.1); <i>p</i> = 0.31]. Tumour progression was the primary reason for treatment discontinuation, and similar access to second-line therapies was observed between the compensated and recompensated groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Patients with cirrhosis and advanced HCC who achieved hepatic recompensation might benefit from systemic therapies after a cautious observation period.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 5","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143809522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response Letter: Steatotic Liver Disease in Younger Adults Is Associated With Altered Gut Microbiology","authors":"Yasmina Tashkent,&nbsp;Jocelyn M. Choo,&nbsp;Leon A. Adams,&nbsp;Geraint B. Rogers","doi":"10.1111/liv.70097","DOIUrl":"https://doi.org/10.1111/liv.70097","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 5","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143809526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ursodeoxycholic Acid Alone Is Effective and Safe to Treat Cholestatic Checkpoint Inhibitor-Induced Liver Injury","authors":"Lina Hountondji,&nbsp;Stéphanie Faure,&nbsp;Pascale Palassin,&nbsp;Georges-Philippe Pageaux,&nbsp;Alexandre Thibault Jacques Maria,&nbsp;Lucy Meunier","doi":"10.1111/liv.70073","DOIUrl":"https://doi.org/10.1111/liv.70073","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Checkpoint Inhibitor-induced Liver Injury (CHILI) is a frequent complication of immune checkpoint inhibitors (ICIs). Corticosteroids are the standard treatment but have many limitations. Ursodeoxycholic acid (UDCA) offers an alternative for managing cholestatic CHILI, but its efficacy remains underexplored.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A multicenter retrospective study included 27 patients treated with first-line UDCA monotherapy. Data were collected from diagnosis to week 52, assessing liver enzyme improvement, recurrence, and outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>UDCA alone achieved improvement in 81.5% of patients, with an average response time of 39.3 days. Among patients, 77.8% had severe CHILI (CTCAE grade ≥ 3). Macroscopic bile duct injury was observed in 37%, associated with higher recurrence rates (75%, <i>p</i> &lt; 0.001). Recurrent CHILI led to chronic CHILI in all cases. ICI rechallenge was conducted in 52% of patients, with only 23% experiencing relapse.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>UDCA monotherapy appears effective for cholestatic CHILI, presenting a viable alternative to corticosteroids. Further prospective studies are warranted.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 5","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70073","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143793583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relative Exchangeable Copper, Exchangeable Copper and Total Copper in the Diagnosis of Wilson Disease","authors":"Camilla Lorenzen,&nbsp;Karen Dons,&nbsp;Clàudia García-Solà,&nbsp;Xavier Forns,&nbsp;Frederik Teicher Kirk,&nbsp;Emilie Munk Lynderup,&nbsp;Karina Stubkjær Rewitz,&nbsp;Anna Soria,&nbsp;Sergio Rodríguez-Tajes,&nbsp;Lene Damm Christensen,&nbsp;Tua Gyldenholm,&nbsp;Peter Nissen Bjerring,&nbsp;Anna Miralpeix,&nbsp;Mercè Torra,&nbsp;Peter Ott,&nbsp;Thomas Damgaard Sandahl,&nbsp;Zoe Mariño","doi":"10.1111/liv.70089","DOIUrl":"https://doi.org/10.1111/liv.70089","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Diagnosing Wilson disease (WD) remains challenging. The exchangeable copper (CuEXC) methodology measures the non-ceruloplasmin-bound copper fraction in serum. Relative exchangeable copper (REC), the ratio of CuEXC to total serum copper (Total Cu), has been proposed as a potential diagnostic biomarker. This study aimed to evaluate the diagnostic performance of these three copper biomarkers in WD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>CuEXC and Total Cu levels were measured in newly diagnosed treatment-naïve patients with WD (<i>n</i> = 13), treated WD (<i>n</i> = 91), non-Wilsonian hepatic disease (<i>n</i> = 206) and non-Wilsonian acute liver failure (<i>n</i> = 22). REC, CuEXC and Total Cu were compared among groups. Receiver-operating characteristic analyses were performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Median REC was significantly elevated among patients with WD compared to all other groups combined (23.6% vs. 4.9%, <i>p</i> &lt; 0.001). The opposite was found for Total Cu (3.5 μmol/L vs. 17.2 μmol/L, <i>p</i> &lt; 0.001). In newly diagnosed patients with WD, median REC was significantly higher than in treated patients (29.1% vs. 21.6%, <i>p</i> = 0.008). The optimal diagnostic cut-off value for REC was ≥ 13.8% (sensitivity 100% and specificity 99.6%) for newly diagnosed patients versus those with non-Wilsonian hepatic disease. For Total Cu, the optimal cut-off was ≤ 7.1 μmol/L (sensitivity 61.5% and specificity 99.1%) for newly diagnosed patients with WD versus those with non-Wilsonian hepatic disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our data support the diagnostic value of REC in WD. The more broadly available Total Cu also demonstrates a strong diagnostic performance and may be useful in initial work-up. We suggest including REC and/or Total Cu in a future revision of the Leipzig score.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 5","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70089","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143793584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Choice of Tariff When Calculating Clinically Meaningful EQ-5D Scores in Metabolic Dysfunction-Associated Steatohepatitis","authors":"James Piercy,&nbsp;Jesse Fishman,&nbsp;Victoria Higgins,&nbsp;James Pike","doi":"10.1111/liv.70043","DOIUrl":"https://doi.org/10.1111/liv.70043","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background &amp; Aims</h3>\u0000 \u0000 <p>Self-reported health varies across countries, as populations attribute different degrees of value to EQ-5D domains. Country-specific EQ-5D tariffs were developed to account for this but are not always stated in the literature. We aim to assess the reporting of EQ-5D in the literature and the impact of applying country-specific tariffs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We reviewed literature-reported EQ-5D utilities for patients with metabolic dysfunction-associated steatohepatitis versus real-world EQ-5D utilities from the Adelphi Real World Non-alcoholic steatohepatitis Disease Specific Programme (DSP), a cross-sectional survey in France, Germany, Italy, Spain, the United Kingdom and the United States. Matching-adjusted indirect comparison analysis balanced DSP data with literature studies by age, sex, comorbidities and fibrosis stage. DSP utility scores generated using national tariffs were compared with literature utilities using weighted t tests.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Ten studies with varying recruitment criteria, patient demographics and clinical characteristics were identified. Country-specific tariffs were not used or not reported. EQ-5D utilities varied, reflecting geographic, clinical and demographic characteristics. The comparison of literature and matched utilities derived using DSP data and five national tariffs revealed ≥ two comparisons for each study with a difference not exceeding the minimal clinically important difference versus the matched DSP value.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Literature-reported EQ-5D utilities vary considerably depending on study methodology and country-specific EQ-5D tariff, and even if stated may not always use the most appropriate tariff. This suggests a need for consistent use of country-specific tariffs and sensitivity analyses confirming results and conclusions that include EQ-5D-based utility measurement to inform decision-making by health authorities.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 5","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70043","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}